# SITIME Corp: financial statements, quarterly

SITM · Nasdaq · CIK 1451809 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sitm.md) · [Financials](/companies/sitm/financials.md) · [Filings](/companies/sitm/filings.md) · [Insiders](/companies/sitm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sitm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [35.5](/filings/0001451809-24-000279.md) | [42.4 d](/filings/0001451809-26-000012.md) | [33.0](/filings/0001451809-25-000088.md) | [43.9](/filings/0001451809-25-000113.md) | [57.7](/filings/0001451809-25-000147.md) | [68.1 d](/filings/0001451809-26-000012.md) | [60.3](/filings/0001451809-26-000041.md) | [69.5](/filings/0001451809-26-000060.md) | [83.6](/filings/0001451809-25-000147.md) | [113 d](/filings/0001451809-26-000012.md) | [114](/filings/0001451809-26-000041.md) | [157](/filings/0001451809-26-000060.md) |
| Cost of revenue | $m | [15.6](/filings/0001451809-24-000279.md) | [18.7 d](/filings/0001451809-26-000012.md) | [15.4](/filings/0001451809-25-000088.md) | [22.3](/filings/0001451809-25-000113.md) | [28.2](/filings/0001451809-25-000147.md) | [32.3 d](/filings/0001451809-26-000012.md) | [30.0](/filings/0001451809-26-000041.md) | [33.4](/filings/0001451809-26-000060.md) | [38.9](/filings/0001451809-25-000147.md) | [49.4 d](/filings/0001451809-26-000012.md) | [46.6](/filings/0001451809-26-000041.md) | [58.3](/filings/0001451809-26-000060.md) |
| Gross profit | $m | [19.9](/filings/0001451809-24-000279.md) | [23.7 d](/filings/0001451809-26-000012.md) | [17.7](/filings/0001451809-25-000088.md) | [21.5](/filings/0001451809-25-000113.md) | [29.5](/filings/0001451809-25-000147.md) | [35.8 d](/filings/0001451809-26-000012.md) | [30.3](/filings/0001451809-26-000041.md) | [36.1](/filings/0001451809-26-000060.md) | [44.7](/filings/0001451809-25-000147.md) | [63.9 d](/filings/0001451809-26-000012.md) | [67.0](/filings/0001451809-26-000041.md) | [99.1](/filings/0001451809-26-000060.md) |
| Research and development | $m | [23.6](/filings/0001451809-24-000279.md) | [22.9 d](/filings/0001451809-26-000012.md) | [25.5](/filings/0001451809-25-000088.md) | [25.5](/filings/0001451809-25-000113.md) | [26.5](/filings/0001451809-25-000147.md) | [29.3 d](/filings/0001451809-26-000012.md) | [30.0](/filings/0001451809-26-000041.md) | [30.6](/filings/0001451809-26-000060.md) | [30.0](/filings/0001451809-25-000147.md) | [28.3 d](/filings/0001451809-26-000012.md) | [32.7](/filings/0001451809-26-000041.md) | [36.1](/filings/0001451809-26-000060.md) |
| Selling, general and administrative | $m | [21.4](/filings/0001451809-24-000279.md) | [20.5 d](/filings/0001451809-26-000012.md) | [23.9](/filings/0001451809-25-000088.md) | [25.2](/filings/0001451809-25-000113.md) | [25.4](/filings/0001451809-25-000147.md) | [27.7 d](/filings/0001451809-26-000012.md) | [26.9](/filings/0001451809-26-000041.md) | [28.2](/filings/0001451809-26-000060.md) | [30.6](/filings/0001451809-25-000147.md) | [30.8 d](/filings/0001451809-26-000012.md) | [38.9](/filings/0001451809-26-000041.md) | [46.3](/filings/0001451809-26-000060.md) |
| Operating income | $m | [(25.2)](/filings/0001451809-24-000279.md) | [(27.5) d](/filings/0001451809-26-000012.md) | [(35.0)](/filings/0001451809-25-000088.md) | [(32.3)](/filings/0001451809-25-000113.md) | [(24.9)](/filings/0001451809-25-000147.md) | [(23.0) d](/filings/0001451809-26-000012.md) | [(28.1)](/filings/0001451809-26-000041.md) | [(24.6)](/filings/0001451809-26-000060.md) | [(16.0)](/filings/0001451809-25-000147.md) | [1.8 d](/filings/0001451809-26-000012.md) | [(12.3)](/filings/0001451809-26-000041.md) | [8.2](/filings/0001451809-26-000060.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001451809-26-000060.md) | not reported | not reported | not reported | [2.2](/filings/0001451809-26-000060.md) |
| Income tax | $m | [0.0](/filings/0001451809-24-000279.md) | [0.0 d](/filings/0001451809-26-000012.md) | [0.0](/filings/0001451809-25-000088.md) | [(0.0)](/filings/0001451809-25-000113.md) | [0.1](/filings/0001451809-25-000147.md) | [0.4 d](/filings/0001451809-26-000012.md) | [0.1](/filings/0001451809-26-000041.md) | [0.0](/filings/0001451809-26-000060.md) | [0.1](/filings/0001451809-25-000147.md) | [0.4 d](/filings/0001451809-26-000012.md) | [0.0](/filings/0001451809-26-000041.md) | [0.0](/filings/0001451809-26-000060.md) |
| Net income | $m | [(18.1)](/filings/0001451809-24-000279.md) | [(20.0) d](/filings/0001451809-26-000012.md) | [(28.7)](/filings/0001451809-25-000088.md) | [(26.8)](/filings/0001451809-25-000113.md) | [(19.3)](/filings/0001451809-25-000147.md) | [(18.8) d](/filings/0001451809-26-000012.md) | [(23.9)](/filings/0001451809-26-000041.md) | [(20.2)](/filings/0001451809-26-000060.md) | [(8.0)](/filings/0001451809-25-000147.md) | [9.2 d](/filings/0001451809-26-000012.md) | [(5.2)](/filings/0001451809-26-000041.md) | [18.2](/filings/0001451809-26-000060.md) |
| Diluted EPS | $ per share | [(0.81)](/filings/0001451809-24-000279.md) | not reported | [(1.26)](/filings/0001451809-25-000088.md) | [(1.16)](/filings/0001451809-25-000113.md) | [(0.83)](/filings/0001451809-25-000147.md) | not reported | [(1.01)](/filings/0001451809-26-000041.md) | [(0.84)](/filings/0001451809-26-000060.md) | [(0.31)](/filings/0001451809-25-000147.md) | not reported | [(0.20)](/filings/0001451809-26-000041.md) | [0.66](/filings/0001451809-26-000060.md) |
| Basic EPS | $ per share | [(0.81)](/filings/0001451809-24-000279.md) | not reported | [(1.26)](/filings/0001451809-25-000088.md) | [(1.16)](/filings/0001451809-25-000113.md) | [(0.83)](/filings/0001451809-25-000147.md) | not reported | [(1.01)](/filings/0001451809-26-000041.md) | [(0.84)](/filings/0001451809-26-000060.md) | [(0.31)](/filings/0001451809-25-000147.md) | not reported | [(0.20)](/filings/0001451809-26-000041.md) | [0.69](/filings/0001451809-26-000060.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Current assets | $m | [667](/filings/0001451809-24-000015.md) | [623](/filings/0001451809-25-000034.md) | [618](/filings/0001451809-24-000110.md) | [554](/filings/0001451809-24-000220.md) | [546](/filings/0001451809-24-000279.md) | [544](/filings/0001451809-26-000012.md) | [519](/filings/0001451809-25-000088.md) | [919](/filings/0001451809-25-000113.md) | [932](/filings/0001451809-25-000147.md) | [949](/filings/0001451809-26-000060.md) | [949](/filings/0001451809-26-000041.md) | [2,134](/filings/0001451809-26-000060.md) |
| Total assets | $m | [748](/filings/0001451809-24-000015.md) | [952](/filings/0001451809-25-000034.md) | [943](/filings/0001451809-24-000110.md) | [879](/filings/0001451809-24-000220.md) | [878](/filings/0001451809-24-000279.md) | [885](/filings/0001451809-26-000012.md) | [872](/filings/0001451809-25-000088.md) | [1,269](/filings/0001451809-25-000113.md) | [1,277](/filings/0001451809-25-000147.md) | [1,295](/filings/0001451809-26-000060.md) | [1,293](/filings/0001451809-26-000041.md) | [2,506](/filings/0001451809-26-000060.md) |
| Current liabilities | $m | [31.3](/filings/0001451809-24-000015.md) | [121](/filings/0001451809-25-000034.md) | [119](/filings/0001451809-24-000110.md) | [80.4](/filings/0001451809-24-000220.md) | [94.9](/filings/0001451809-24-000279.md) | [108](/filings/0001451809-26-000012.md) | [107](/filings/0001451809-25-000088.md) | [108](/filings/0001451809-25-000113.md) | [111](/filings/0001451809-25-000147.md) | [84.0](/filings/0001451809-26-000060.md) | [76.1](/filings/0001451809-26-000041.md) | [110](/filings/0001451809-26-000060.md) |
| Total liabilities | $m | [37.3](/filings/0001451809-24-000015.md) | [244](/filings/0001451809-25-000034.md) | [246](/filings/0001451809-24-000110.md) | [186](/filings/0001451809-24-000220.md) | [182](/filings/0001451809-24-000279.md) | [185](/filings/0001451809-26-000012.md) | [180](/filings/0001451809-25-000088.md) | [168](/filings/0001451809-25-000113.md) | [174](/filings/0001451809-25-000147.md) | [139](/filings/0001451809-26-000060.md) | [134](/filings/0001451809-26-000041.md) | [1,480](/filings/0001451809-26-000060.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [710](/filings/0001451809-24-000279.md) | [708](/filings/0001451809-26-000012.md) | [696](/filings/0001451809-25-000113.md) | [693](/filings/0001451809-25-000147.md) | [696](/filings/0001451809-25-000147.md) | [700](/filings/0001451809-26-000060.md) | [693](/filings/0001451809-26-000060.md) | [1,101](/filings/0001451809-26-000060.md) | [1,103](/filings/0001451809-25-000147.md) | [1,156](/filings/0001451809-26-000060.md) | [1,159](/filings/0001451809-26-000060.md) | [1,025](/filings/0001451809-26-000060.md) |

- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.6) d](/filings/0001451809-24-000279.md) | [(1.4) d](/filings/0001451809-26-000012.md) | [1.7](/filings/0001451809-25-000088.md) | [(0.2) d](/filings/0001451809-25-000113.md) | [8.2 d](/filings/0001451809-25-000147.md) | [13.5 d](/filings/0001451809-26-000012.md) | [15.0](/filings/0001451809-26-000041.md) | [15.3 d](/filings/0001451809-26-000060.md) | [31.4 d](/filings/0001451809-25-000147.md) | [25.4 d](/filings/0001451809-26-000012.md) | [31.2](/filings/0001451809-26-000041.md) | [39.8 d](/filings/0001451809-26-000060.md) |
| Capital expenditure | $m | [2.4 d](/filings/0001451809-24-000279.md) | [2.8 d](/filings/0001451809-26-000012.md) | [2.9](/filings/0001451809-25-000088.md) | [2.6 d](/filings/0001451809-25-000113.md) | [14.9 d](/filings/0001451809-25-000147.md) | [15.9 d](/filings/0001451809-26-000012.md) | [16.3](/filings/0001451809-26-000041.md) | [18.2 d](/filings/0001451809-26-000060.md) | [5.1 d](/filings/0001451809-25-000147.md) | [12.4 d](/filings/0001451809-26-000012.md) | [13.3](/filings/0001451809-26-000041.md) | [12.4 d](/filings/0001451809-26-000060.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.6](/filings/0001451809-24-000015.md) | [21.8](/filings/0001451809-24-000110.md) | [22.1](/filings/0001451809-24-000220.md) | [22.3](/filings/0001451809-24-000279.md) | [22.8](/filings/0001451809-25-000088.md) | [23.0](/filings/0001451809-25-000113.md) | [23.2](/filings/0001451809-25-000147.md) | [23.7](/filings/0001451809-26-000041.md) | [23.9](/filings/0001451809-26-000060.md) | [26.0](/filings/0001451809-25-000147.md) | [26.3](/filings/0001451809-26-000041.md) | [27.5](/filings/0001451809-26-000060.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,071,036 at 2026-08-01, from the cover of the [10-Q filed 2026-08-06](/filings/0001451809-26-000060.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.